

James E Tisdale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3409548/publications.pdf>

Version: 2024-02-01

97
papers

3,094
citations

201674

27
h-index

161849

54
g-index

108
all docs

108
docs citations

108
times ranked

3473
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 479-487.	2.2	275
2	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, e153-e193.	0.8	236
3	Torsades de Pointes Associated With Intravenous Haloperidol in Critically Ill Patients. <i>American Journal of Cardiology</i> , 1998, 81, 238-240.	1.6	232
4	QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. <i>Current Medical Research and Opinion</i> , 2013, 29, 1719-1726.	1.9	175
5	Drug-induced QT interval prolongation and torsades de pointes. <i>Canadian Pharmacists Journal</i> , 2016, 149, 139-152.	0.8	151
6	Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e214-e233.	1.6	136
7	Atrial Fibrillation After Bypass Surgery. <i>Chest</i> , 1998, 113, 1489-1491.	0.8	110
8	The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery: Executive Summary. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1144-1152.	1.3	109
9	A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 45-51.	0.8	97
10	Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Progress in Cardiovascular Diseases</i> , 1995, 38, 167-180.	3.1	93
11	A Randomized Trial Evaluating Amiodarone for Prevention of Atrial Fibrillation After Pulmonary Resection. <i>Annals of Thoracic Surgery</i> , 2009, 88, 886-895.	1.3	93
12	A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. <i>American Heart Journal</i> , 1998, 135, 739-747.	2.7	91
13	Prevalence of QT Interval Prolongation in Patients Admitted to Cardiac Care Units and Frequency of Subsequent Administration of QT Interval-Prolonging Drugs. <i>Drug Safety</i> , 2012, 35, 459-470.	3.2	74
14	Proarrhythmic Effects of Intravenous Vasopressors. <i>Annals of Pharmacotherapy</i> , 1995, 29, 269-281.	1.9	70
15	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 772-791.	0.8	69
16	Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence. <i>Progress in Cardiovascular Diseases</i> , 2001, 44, 121-152.	3.1	64
17	Effectiveness of a Clinical Decision Support System for Reducing the Risk of QT Interval Prolongation in Hospitalized Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 381-390.	2.2	64
18	The Effect of Intravenous Haloperidol on QT Interval Dispersion in Critically Ill Patients: Comparison with QT Interval Prolongation for Assessment of Risk of Torsades de Pointes. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1310-1318.	2.0	59

#	ARTICLE	IF	CITATIONS
19	Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 242-247.	4.7	58
20	Drug-Induced Atrial Fibrillation. <i>Drugs</i> , 2012, 72, 1617-1630.	10.9	57
21	Risk factors for hypertensive crisis: importance of out-patient blood pressure control. <i>Family Practice</i> , 2004, 21, 420-424.	1.9	52
22	Risk Factors for the Development of Specific Noncardiovascular Adverse Effects Associated With Amiodarone. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 351-356.	2.0	41
23	Effect of Drugs on Defibrillation Capacity. <i>Drugs</i> , 2008, 68, 607-630.	10.9	40
24	Experiential Training for Pharmacy Students: Time for a New Approach. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 285-93.	0.1	40
25	Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 5-26.	1.3	36
26	Efavirenz Inhibits the Human Ether-à-go-go Related Current (hERG) and Induces QT Interval Prolongation in <i>CYP2B6</i> Allele Carriers. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1206-1213.	1.7	35
27	Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. <i>Pharmacotherapy</i> , 2018, 38, 813-821.	2.6	34
28	Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 1500-1505.	3.2	27
29	Prophylaxis of Atrial Fibrillation After Noncardiac Thoracic Surgery. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2010, 22, 310-320.	0.6	26
30	Chloroquine and Hydroxychloroquine in the Era of SARS-CoV2: Caution on Their Cardiac Toxicity. <i>Pharmacotherapy</i> , 2020, 40, 387-388.	2.6	24
31	Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 765-774.	3.2	23
32	Accuracy of Uncorrected versus Corrected QT Interval for Prediction of Torsade de Pointes Associated with Intravenous Haloperidol. <i>Pharmacotherapy</i> , 2007, 27, 175-182.	2.6	21
33	Hemodynamic and Neurohormonal Predictors and Consequences of the Development of Atrial Fibrillation in Dogs With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, 747-751.	1.7	20
34	Ondansetron blocks wild-type and p.F503L variant small-conductance Ca^{2+} -activated K^{+} channels. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H375-H388.	3.2	18
35	High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4495-4499.	3.2	17
36	Enhanced Sensitivity to Drug-Induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1296-1305.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. <i>Applied Clinical Informatics</i> , 2016, 07, 1088-1106.	1.7	16
38	Disposition of Procainamide in Patients with Chronic Congestive Heart Failure Receiving Medical Therapy. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 35-41.	2.0	14
39	Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men. <i>Circulation</i> , 2019, 140, 1127-1129.	1.6	14
40	The Effect of Haloperidol on Ventricular Fibrillation Threshold in Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 69, 327-329.	0.0	13
41	Relationship Between Serum Concentration and Dose of Valproic Acid During Monotherapy in Adult Outpatients. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 416-423.	2.0	13
42	Bleeding Associated with Eptifibatid Targeting Higher Risk Patients with Acute Coronary Syndromes: Incidence and Multivariate Risk Factors. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1366-1373.	2.0	13
43	Pharmacokinetics of Ibutilide in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction. <i>Pharmacotherapy</i> , 2008, 28, 1461-1470.	2.6	13
44	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	4.8	13
45	A Systematic Review of Palpitations Prevalence by Menopausal Status. <i>Current Obstetrics and Gynecology Reports</i> , 2021, 10, 7-13.	0.8	12
46	The Use of Calcium Salts in the Prevention and Management of Verapamil-Induced Hypotension. <i>Annals of Pharmacotherapy</i> , 2000, 34, 622-629.	1.9	11
47	The Influence of Progesterone Alone and in Combination With Estradiol on Ventricular Action Potential Duration and Triangulation in Response to Potassium Channel Inhibition. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 325-331.	1.7	11
48	A Menopause Strategiesâ€œFinding Lasting Answers for Symptoms and Health (MsFLASH) Investigation of Self-Reported Menopausal Palpitation Distress. <i>Journal of Women's Health</i> , 2021, 30, 533-538.	3.3	11
49	Influence of IV Haloperidol on Ventricular Repolarization and Monophasic Action Potential Duration in Anesthetized Dogs. <i>Chest</i> , 2004, 125, 1821-1829.	0.8	10
50	Methadoneâ€œassociated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. <i>Pharmacotherapy</i> , 2021, 41, 238-246.	2.6	10
51	Streptokinase-Induced Anaphylaxis. <i>DICP: the Annals of Pharmacotherapy</i> , 1989, 23, 984-987.	0.2	9
52	Amiodarone for prevention of atrial fibrillation following esophagectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 301-310.e1.	0.8	9
53	Antifibrillatory Effect of Esmolol Alone and in Combination with Lidocaine. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 376-382.	1.9	9
54	Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel Approach to Guide Renal Dose Adjustments. <i>American Journal of Kidney Diseases</i> , 2013, 61, 1046-1048.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Review of menopausal palpitations measures. <i>Women's Midlife Health</i> , 2021, 7, 5.	1.5	8
56	Inhibition of Nâ€Acetylation of Procainamide and Renal Clearance of Nâ€Acetylprocainamide by Paraâ€Aminobenzoic Acid in Humans. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 902-910.	2.0	7
57	Prospective evaluation of serum amiodarone concentrations when administered via a nasogastric tube into the stomach conduit after transthoracic esophagectomy. <i>Clinical Therapeutics</i> , 2007, 29, 2226-2234.	2.5	7
58	Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 671-677.	1.7	7
59	Lidocaine prophylaxis in acute myocardial infarction. <i>Henry Ford Hospital Medical Journal</i> , 1991, 39, 217-25.	0.1	7
60	Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 1274-1280.	1.8	6
61	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	4.8	6
62	Progesterone pretreatment reduces the incidence of drugâ€induced torsades de pointes in atrioventricular nodeâ€ablated isolated perfused rabbit hearts. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 941-949.	1.7	5
63	What Causes Some Patients with Drug-Induced QT Interval Prolongation to Develop Torsades de Pointes but Not Others? The Elusive Missing Link. <i>Drugs and Aging</i> , 2014, 31, 577-579.	2.7	4
64	Prevalence and significance of acquired QT interval prolongation in hospitalized patients. <i>Heart Rhythm</i> , 2017, 14, 979-980.	0.7	4
65	Proarrhythmic food for thought. <i>Heart Rhythm</i> , 2019, 16, 1149-1150.	0.7	4
66	Navigating the Minefield of QTc Intervalâ€Prolonging Therapy in Nursing Facility Residents. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1508-1515.	2.6	3
67	MsFLASH analysis of diurnal salivary cortisol and palpitations in peri- and postmenopausal women. <i>Menopause</i> , 2022, 29, 144-150.	2.0	3
68	Erratum to â€œThe Effect of Intravenous Haloperidol on QT Interval Dispersion in Critically Ill Patients: Comparison with QT Interval Prolongation for Assessment of Risk of Torsades de Pointesâ€[<i>J Clin Pharmacol</i> 2001;41:1310-1318]. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 577-579.	2.0	2
69	Integrity in Authorship and Publication. <i>Canadian Journal of Hospital Pharmacy</i> , 2009, 62, 441-7.	0.1	2
70	Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 183-4.	0.1	2
71	Progesterone Metabolites Inhibit the Human Etherâ€goâ€Related Gene and Predict QT Interval Length. <i>Journal of Clinical Pharmacology</i> , 2019, 60, 648.	2.0	2
72	Enhanced Response to Drug-Induced QT Interval Lengthening in Patients with Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 781-785.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Accuracy of a single-lead mobile smartphone electrocardiogram for QT interval measurement in patients undergoing maintenance methadone therapy. <i>Pharmacotherapy</i> , 2021, 41, 494-500.	2.6	2
74	Effect of menopausal symptom treatment options on palpitations: a systematic review. <i>Climacteric</i> , 2021, , 1-13.	2.4	2
75	Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	2
76	Role of the pharmacist in managing hypertension in patients with diabetes. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1129-1129.	1.0	1
77	Paroxysmal β -adrenergic Receptor-mediated Alterations in Ventricular Repolarization at Rapid Heart Rates During Inhibition of Delayed Rectifier Currents. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 54, 253-262.	1.9	1
78	Pharmacists and Cardiologists in the ACC. <i>Journal of the American College of Cardiology</i> , 2019, 74, 470-472.	2.8	1
79	Editorial commentary: Amiodarone-induced thyroid diseases: Additional unintended consequences. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 296-297.	4.9	1
80	Transdermal Testosterone Attenuates Drug-Induced Lengthening of Both Early and Late Ventricular Repolarization in Older Men. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1499-1504.	4.7	1
81	Comparison of Fluorescence Polarization Immunoassay with Liquid Chromatography for Quantification of Procainamide and N-Acetylprocainamide in Urine. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 693-697.	2.0	1
82	Research Conducted by Hospital Pharmacists: Integral Component of Daily Practice or Unrealistic Expectation?. <i>Canadian Journal of Hospital Pharmacy</i> , 2018, 71, 95-96.	0.1	1
83	Accuracy of unbound-quinidine concentration determination after ultrafiltration. <i>Clinical Pharmacy</i> , 1993, 12, 917-21.	0.2	1
84	Testosterone does not shorten action potential duration in Langendorff-perfused rabbit ventricles. <i>Heart Rhythm</i> , 2022, 19, 1864-1871.	0.7	1
85	Correlates of palpitations during menopause: A scoping review. <i>Women's Health</i> , 2022, 18, 174550572211122.	1.5	1
86	Efficacy of Class 1C Antiarrhythmic Agents in Patients With Inducible Ventricular Tachycardia Refractory to Therapy With Class 1A Antiarrhythmic Drugs. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 623-630.	2.0	0
87	Toward a Unified Model for Contemporary Institutional Pharmacy Practice. <i>Canadian Journal of Hospital Pharmacy</i> , 2011, 64, 97-103.	0.1	0
88	Hospital Pharmacy in Canada: Ahead of the Curve. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 345-50.	0.1	0
89	Can I Get a Guideline to Help Me Interpret Treatment Guidelines?. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 181-2.	0.1	0
90	Editorial Commentary: Optimization of dose selection for nonvitamin K antagonist oral anticoagulants. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 573-574.	4.9	0

#	ARTICLE	IF	CITATIONS
91	Abstract 18740: Influence of Oral Progesterone Administration on QT Interval Response to Ikr Inhibition. Circulation, 2014, 130, .	1.6	0
92	Abstract 13786: Contribution of Medications and Risk Factors to QT Interval Lengthening in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2014, 130, .	1.6	0
93	Are antiarrhythmic drugs obsolete?. Clinical Pharmacy, 1992, 11, 714-26.	0.2	0
94	Combination antiarrhythmic therapy. Connecticut Medicine, 1989, 53, 101-5.	0.2	0
95	Traditional risk factors for QT interval prolongation and torsades de pointes. , 2022, , 79-111.		0
96	Predictive analytics for reducing the risk of QT interval prolongation and torsades de pointes. , 2022, , 157-181.		0
97	Abstract 19035: Cardiovascular QTc Interval-Prolonging Medications and the Risk of Death, Stroke and Incident Atrial Fibrillation in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2015, 132, .	1.6	0